Piperazine-derived lipid nanoparticles deliver mRNA to immune cells in vivo

In humans, lipid nanoparticles (LNPs) have safely delivered therapeutic RNA to hepatocytes after systemic administration and to antigen-presenting cells after intramuscular injection. However, systemic RNA delivery to non-hepatocytes remains challenging, especially without targeting ligands such as...

Descripción completa

Detalles Bibliográficos
Autores principales: Ni, Huanzhen, Hatit, Marine Z. C., Zhao, Kun, Loughrey, David, Lokugamage, Melissa P., Peck, Hannah E., Cid, Ada Del, Muralidharan, Abinaya, Kim, YongTae, Santangelo, Philip J., Dahlman, James E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9376583/
https://www.ncbi.nlm.nih.gov/pubmed/35970837
http://dx.doi.org/10.1038/s41467-022-32281-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9376583/
https://www.ncbi.nlm.nih.gov/pubmed/35970837
http://dx.doi.org/10.1038/s41467-022-32281-5

Ejemplares similares